Drugs / LXR-623
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00379860 | Oct 2006 → Jan 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00366522 | Aug → Sep 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00385489 | Aug → Sep 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LXR-623 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00379860 ↗ |
| Known as | LX-623 | ChEMBL registry synonym — accepted as the source's own label CHEMBL456237 ↗ |
| Known as | LXR-623 (WAY-252623) | ChEMBL registry synonym — accepted as the source's own label CHEMBL456237 ↗ |
| Known as | WAY 252623 | ChEMBL registry synonym — accepted as the source's own label CHEMBL456237 ↗ |
| Action | Activate | “LXR-alpha agonist” CHEMBL456237 ↗1“LXR-beta agonist” CHEMBL456237 ↗ |
| Modality | Small molecule | — CHEMBL456237 ↗ |
| Route | Oral | “LXR-623 Administered Orally to Healthy Subjects” NCT00366522 ↗ |
| Target | NR1H2 | “LXR-beta agonist” CHEMBL456237 ↗ |
| Target | NR1H3 | “LXR-alpha agonist” CHEMBL456237 ↗ |